Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance.
Kantarjian
Hagop
H
Leukemia Department, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
le Coutre
Phillipp
P
Cortes
Jorge
J
Pinilla-Ibarz
Javier
J
Nagler
Arnon
A
Hochhaus
Andreas
A
Kimura
Shinya
S
Ottmann
Oliver
O
D000293:Adolescent; D000328:Adult; D000368:Aged; D001549:Benzamides; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C506918:bafetinib